Use of Botulinum Toxin in Neurology

Czech version

Authors: doc. MUDr. Edvard Ehler, CSc.
Authors‘ workplace: Neurologická klinika FZS Univerzity Pardubice a Pardubické krajské nemocnice, a. s.
Published in: Cesk Slov Neurol N 2013; 76/109(1): 7-21
Category: Minimonography

Overview

Botulinum toxin is one of the strongest natural toxins. The toxin is produced by anaerobic bacteria Clostridium botulinum. The substance causes a block of acetylcholine release on the neuromuscular endplate with subsequent disruption of impulse transmission on the muscle. At the same time, botulinum toxin causes denervation syndrome of the muscle into which it was administered. There are seven types of botulinum toxin with effects on various proteins in presynaptic ending. In contemporary clinical practice, botulinum toxin has been used for more than 30 years and drugs with botulinum toxin A and B are available. At present, two medicinal products containing botulinum toxin A (Botox^® and Dysport^®) and one with botulinum toxin B (NeuroBloc^®) are available. Botulinum toxin is a highly effective drug used in many clinical conditions associated with increased skeletal muscle activity and increased activity of autonomic system. Botulinum toxin is indicated and reimbursed by insurance companies for cervical dystonia, other dystonias, blepharospasm, hemifacialis spasm, upper limb spasticity after stroke, and upper and lower limb spasticity in cerebral palsy. It also has proven efficacy in chronic headache, sfincter-detrusor dyssynergia of urine bladder, hyperhidrosis, sialorhoea, in gastroenterologic disorders (achalasia, anal fissure), cosmetic indications and in a number of other conditions. Contraindications include pregnancy, lactation, some neuromuscular diseases, haemocoagulation disorders including anticoagulation therapy (INR > 2.8) and inflammatory changes of the skin at the administration site. Adverse events include intensive muscle weakness, pain, hemorrhage into the muscle or subcutaneous tissue, headache as well as flu-like symptoms. Botulinum toxin is injected into muscles or subcutaneous tissue either directly “from hand“, guided by EMG signal with a support of hollow monopolar EMG needle electrode, by direct stimulation of the muscle with hollow EMG needle electrode, guided by ultrasonography (position of the needle and the belly of a muscle) or CT.

Key words:
botulinum toxin – neuromuscular transmission – chemodenervation – dystonia – spasticity

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Sources

1. Barnes MP, Johnson GR (eds). Upper motor neurone syndrome and spasticity. Clinical management and neurophysiology. 2^nd ed. Cambridge: Cambridge University Press 2001.

2. Panicker JN, Muthane UB. Botulinum toxins: pharmocology and its current therapeutic evidence for use. Neurol India 2003; 51(4): 455–460.

3. Jankovic J, Albanese A, Attassi MZ et al (eds). Botulinum toxin. Therapeutic clinical practice and science. Philadelphia: Saunders Elsevier 2009.

4. Adamová B, Leberová D, Voháňka S, Bednařík J, Bartošíková L. Dlouhodobý vzdálený účinek lokálně aplikovaného botulotoxinu A na nervosvalový přenos. Cesk Slov Neurol N 2003; 66/99(3): 174–177.

5. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord 2011; 17 (Suppl 1): S528–S533.

6. Kanovsky P, Slawek J, Denes Z, Platz T, Comes G, Grafe S et al. Efficacy and safety of treatment with incobotulinumtoxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehab Med 2011; 43(6): 486–492.

7. Albanese A. The current status and use of botulinum toxins. Eur J Neurol 2001; 8 (Suppl 4): 3–7.

8. Lim EH, Quek AM, Seet RC. Accurate targeting of botulinum toxin injections: how to and why. Parkinsonism Relat Disord 2011; 17 (Suppl 1): S534–S539.

9. Comella CL, Pullman SL. Botulinum toxins in neurological disease. Muscle Nerve 2004; 29(5): 628–644.

10. Růžička E. Neurodegenerativní onemocnění mozku. In: Bednařík J, Ambler Z, Růžička E et al (eds). Klinická neurologie. Praha: Triton 2010: 541–707.

11. Fahn S, List T, Moslowitz C, Brin M, Bressman SB, Burke RE et al. Double-blind controlled study of botulinum toxin for blepharospasm. Neurology 1985; 35 (Suppl 1): 271–272.

12. Dutton JJ, White JJ, Richard MJ. Myobloc for the treatment of bening essential blepharospasm in patients refractory to botox. Ophthal Plast Reconstr Surg 2006; 22(3): 173–177.

13. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999; 53(9): 2102–2107.

14. Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE. Botulinum toxin (BOTOX) for the treatment of “spastic dysphonia” as part of a trial of toxin injections for the treatment of other cranial dystonias. Laryngoscope 1986; 96(11): 1300–1301.

15. Kaji R. New and emerging indications of botulinum toxin therapy. Parkinsonism Relat Disord 2011; 17 (Suppl 1): S25–S27.

16. Ward AB. A literature review of the pathophysiology and onset of post-stroke spasticity. Eur J Neurol 2012; 19(1): 21–27.

17. Biering-Sørensen F, Nielsen JB, Klinge K. Spasticity-assessment: a review. Spinal Cord 2006; 44(12): 708–722.

18. Štětkářová I, Ehler E, Jech R. Spasticita a její léčba. Praha: Maxdorf 2012.

19. Shaw L, Rodgers H. Botulinum toxin type A for upper limb spasticity after stroke. Expert Rev Neurother 2009; 9(12): 1713–1725.

20. Brainin M, Norrving B, Sunnerhagen KS, Goldstein LB, Cramer SC, Donnan GA et al. International PSS Disability Study Group. Poststroke chronic disease management: towards improved identification and interventions for poststroke spasticity-related complications. Int J Stroke 2011; 6(2): 42–46.

21. Kaňovský P, Bareš M, Dufek J et al (eds). Spasticita. Mechanismy, diagnostika, léčba. Praha: Maxdorf 2004.

22. Ehler E, Vaňásková E, Štětkářová I. Standard komplexní léčby spasticity po cévní mozkové příhodě. Cesk Slov Neurol N 2009; 72/105(2): 179–181.

23. Kanovsky P, Bares M, Severa S, Richardson A. Dysport Paediatric Limb Spasticity Study Group. Long--term efficacy and tolerability of 4-monthly versus yearly botulinum toxin type A treatment for lower-limb spasticity in children with cerebral palsy. Dev Med Child Neurol 2009; 51(6): 436–445.

24. Kraus J et al (eds). Dětská mozková obrna. Praha: Grada Publishing 2005.

25. Malhotra S, Pandyan AD, Rosewilliam S, Roffe C, Hermens H. Spasticity and contractures of the wrist after stroke: time course of development and their association with functional recovery of the upper limb. Clin Rehabil 2011; 25(2): 184–191.

26. Dobkin BH. Clinical practice. Rehabilitation after stroke. N Engl J Med 2005; 352(16): 1677–1684.

27. Rekand T. Clinical assessment and management of spasticity: a review. Acta Neurol Scand 2010; 190 (Suppl): 62–66.

28. Bakheit AM, Thilman AF, Ward AB, Poewe W, Wissel J, Muller J et al. A randomized double--blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31(10): 2402–2406.

29. Pittock SJ, Moore AP, Hardinamn O, Ehler E, Kovac M, Bojakowski J et al. A double blind randomized placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovas Dis 2003; 15(4): 289–300.

30. Welmer AK, Widén Holmquist L, Sommerfeld DK. Location and severity of spasticity in the first 1–2 weeks and at 3 and 18 months after stroke. Eur J Neurol 2010; 17(5): 720–725.

31. Rosales RL, Kong KH, Goh KJ, Kumthornhip W, Mok VC, Delgado-De Los Santos MM et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair 2012; 26(7): 812–821.

32. Ehler E, Štětkářová I. Botulotoxin v léčbě spasticity. Cesk Slov Neurol N 2009; 72/105(4): 317–321.

33. Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryce RE et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011; 51(9): 1358–1373.

34. Ehler E. Nové perspektivy botulotoxinu. Neurol Prax 2009; 10(2): 91–93.

35. Childers MK, Wilson DJ, Gnatz SM, Conway RR, Sherman AK. Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil 2002; 81(10): 751–759.

36. Kern U, Martin C, Scheicher S, Müller H. Botulinum-Toxin-A in der Behandlung von Phantomscherzen. Eine Pilotstudie. Schmerz 2003; 17(2): 117–124.

37. Aoki KR. Future aspects of botulinum neurotoxins. J Neural Transm 2008; 115(4): 567–573.

38. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overacticity: a randomized, double-blind, placebo-controlled trial. Eur Urol 2011; 60(4): 742–750.